` XCUR (Exicure Inc) vs S&P 500 Comparison - Alpha Spread

XCUR
vs
S&P 500

Over the past 12 months, XCUR has underperformed S&P 500, delivering a return of -66% compared to the S&P 500's +14% growth.

Stocks Performance
XCUR vs S&P 500

Loading
XCUR
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
XCUR vs S&P 500

Loading
XCUR
S&P 500
Difference
www.alphaspread.com

Performance By Year
XCUR vs S&P 500

Loading
XCUR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Exicure Inc vs Peers

S&P 500
XCUR
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Exicure Inc
Glance View

Market Cap
37.5m USD
Industry
Biotechnology

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 47 full-time employees. The company went IPO on 2018-05-09. The firm is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The firm develops XCUR-FXN, which is a spherical nucleic acid (SNA) -based therapeutic candidate for the treatment of Friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.

XCUR Intrinsic Value
Not Available
Back to Top